Disease · MONDO_0006608
Comparisons in its trials12
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 12 of 12
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Roflumilast Foam 0.3% vs Vehicle Foam: deaths from any cause | 0 of 304 | 0 of 153 | 457 | NCT04973228 | Trial comparisons |
| Roflumilast Foam 0.3% vs Vehicle Foam: serious adverse events | 1 of 304 | 0 of 153 | 457 | NCT04973228 | Trial comparisons |
| Roflumilast Foam 0.3% vs Vehicle Foam: deaths from any cause | 0 of 154 | 0 of 72 | 226 | NCT04091646 | Trial comparisons |
| Roflumilast Foam 0.3% vs Vehicle Foam: serious adverse events | 0 of 154 | 0 of 72 | 226 | NCT04091646 | Trial comparisons |
| Roflumilast Foam 0.3% vs Vehicle Foam: Achievement of Investigator Global Assessment (IGA) Success at Week 8 | 104 of 141 | 27 of 66 | 207 | NCT04091646 | Trial comparisons |
| Elidel Cream (Pimecrolimus) vs Ketoconazole Cream (Nizoral): Key Secondary Efficacy Will be the % of Patients With Facial Clearance | 56 of 56 | 56 of 56 | 112 | NCT00403559 | Trial comparisons |
| Elidel Cream vs Ketoconazole Cream: deaths from any cause | 0 of 56 | 0 of 56 | 112 | NCT00403559 | Trial comparisons |
| Elidel Cream vs Ketoconazole Cream: serious adverse events | 0 of 56 | 0 of 56 | 112 | NCT00403559 | Trial comparisons |
| Adults vs Children: deaths from any cause | 0 of 35 | 0 of 42 | 77 | NCT03830177 | Trial comparisons |
| Adults vs Children: serious adverse events | 0 of 35 | 0 of 42 | 77 | NCT03830177 | Trial comparisons |
| Ruxolitinib Cream vs Healthy Control Subjects: deaths from any cause | 0 of 25 | 0 of 20 | 45 | NCT05787860 | Trial comparisons |
| Ruxolitinib Cream vs Healthy Control Subjects: serious adverse events | 0 of 25 | 0 of 20 | 45 | NCT05787860 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0006608/comparisons